Drug Trial Radar · NCT01867125
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,081
Actual
Start
Jul 25, 2013
Primary completion
Dec 28, 2016
Study completion Dec 28, 2016
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. During double-blind active treatment extension period, all participants will receive SC injection of lebrikizumab from Week 53 to Week 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.
Conditions
- Asthma
Interventions
LebrikizumabDrug
Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
PlaceboDrug
Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Exacerbation Rate of Asthma During the 52-Week PCPTime frame: Baseline up to 52 weeks
Locations
181 sites in 26 countries. Site status is shown where the registry gives one.
Alabama Clinical Research Associates
Pell City, Alabama
Desert Sun Clinical Research LLC
Tucson, Arizona
Allianz Medical and Research Center
Fountain Valley, California
Allergy & Asthma Medical Group & Research Center, Pc
Long Beach, California
Allergy Medical Clinic
Los Angeles, California
CA Allergy & Asthma Med Grp
Los Angeles, California
North Bay Clinical Trials
Napa, California
Choc Psf, Amc
Orange, California
Advances in Medicine
Rancho Mirage, California
Allergy Assoc Medical Group
San Diego, California
Bensch Research Associates
Stockton, California
IMMUNOe Research Centers
Centennial, Colorado
Waterbury Pulmonary Associates
Waterbury, Connecticut
St. Francis Sleep; Allergy & Lung Institute
Clearwater, Florida
Suncoast Research Group LLC
Miami, Florida
Emerald Coast Research Associates
Panama City, Florida
Allergy & Asthma Diagnostic; Treatment Center
Tallahassee, Florida
Florida Pulmonary Research Institute, LLC
Winter Park, Florida
Atlanta Allergy & Asthma Clini
Woodstock, Georgia
Northeast Medical Research Associates, Inc
North Dartmouth, Massachusetts
Midwest Clinical Research LLC
St Louis, Missouri
Montana Medical Research LLC
Missoula, Montana
Heartland Clinical Research Inc.
Omaha, Nebraska
Asthma & Allergy Center, P.C.
Papillion, Nebraska
Allergy & Asthma Associates
Las Vegas, Nevada
Allergy & Asthma Research of Nj, Inc
Mount Laurel, New Jersey
Atlantic Research Center, LLC
Ocean City, New Jersey
Princeton Center For Clinical Research
Skillman, New Jersey
Montefiore Medical Center
The Bronx, New York
Allergy & Asthma Center of NC
High Point, North Carolina
PMG Research of Wilmington
Wilmington, North Carolina
Asthma & Allergy Center
Toledo, Ohio
Cor Clinical Research
Oklahoma City, Oklahoma
Allergy & Asthma Research Grp
Eugene, Oregon
Clinical Research Inst. of Southern Oregon, Pc
Medford, Oregon
Allergy Associates Research Center LLC - CRN
Portland, Oregon
Asthma Allergy Pulm Associates
Philadelphia, Pennsylvania
Grand View Hospital; Clinical Research Department
Sellersville, Pennsylvania
Asthma Allergy Phys of RI
Lincoln, Rhode Island
ADAC Research PA
Greenville, South Carolina
Showing 40 of 181 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.